| Sandoz Pharmaceuticals AG - Estalis 50/140, transdermale Pflaster | | 54704 | | 01 | | Estalis 50/140 | | transdermale Pflaster | | G03FA01 | | Norethisterone and Estrogen | | 17.08.1999 | | |
| | Composition | | estradiolum 0.60 mg ut estradiolum hemihydricum 0.62 mg, norethisteroni acetas 2.7 mg, silicone adhesive, acrylic adhesive, povidonum K 30, acidum oleicum, dipropylenglycolum, Trägermaterial: ad praeparationem pro 9 cm², cum liberatione 50 µg et 140 µg/24 h. | | Packungsbestandteile | | Transdermal patch | | | | | Active Agent | Dose |
|---|
| Estradiol | 0.6 mg | | Norethisterone Acetate | 2.7 mg |
| | BAG: Active Agent | Dose |
|---|
| Estradiol | 0.6 mg | | Norethisterone Acetate | 2.7 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| | | | | | | | | | 9 cm | Trägermaterial | | | 50µg et 140 µg / 24h | | | Dipropylenglycol | | | | | 30 | | | | | |
| |
| |
|
